Tags : Idiopathic Pulmonary Fibrosis

Galecto’s GB0139 Receives the US FDA’s and EMA’s Orphan Drug

Shots: The US FDA and EMA has received ODD to Galecto’s GB0139 for the treatment of IPF. GB0139 showed significant reduction of YKL-40 biomarker in fibrosis, inflammation, tissue remodeling diseases in its first clinical study after 14 days of treatment The EMA cited GB0139’s clinically relevant biomarker data in IPF patients which provides financial incentives, […]Read More

AstraZeneca Signs a License Agreement with Redx Pharma for RXC006

Shots: Redx to receive $17M in early payment by the time of successful commencement of a P-I study, $360M as development, a regulatory and commercial milestone along with royalties on sales of the RXC006 AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF Redx continues to […]Read More

AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney

Shots: AstraZeneca & BenevolentAI enter into an agreement to discover & develop therapies for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) utilizing artificial intelligence (AI) and machine learning AstraZeneca will combine its genomics, chemistry and clinical data with Benevolent AI’s target identification platform and biomedical knowledge graph (network of genes, proteins, diseases and […]Read More

Bayer Signs an Exclusive License Agreement with Kyoto University for

Shots: Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the trial The focus of the agreement is to discover targets and develop treatments, with combined techniques of the company in pulmonary disorders including idiopathic pulmonary […]Read More